|
시장보고서
상품코드
1862157
세계의 혈관신생 어세이 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Angiogenesis Assay - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
혈관신생 어세이 세계 시장 규모는 2024년에 2,408만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 7.5%로 성장하여 2031년까지 3,993만 달러로 확대될 것으로 예측됩니다.
혈관 신생은 기존 혈관계에서 새로운 혈관이 형성되는 엄격하게 통제된 과정입니다. 이 과정은 발달과 상처 치유에 있어 생리학적으로 중요하며, 류마티스 관절염, 죽상동맥경화증, 황반변성, 암 등 여러 질환의 공통적인 요인이기도 합니다. 혈관신생은 다양한 분자 신호에 반응하여 발생합니다. 일반적으로 혈관 신생 과정은 내피세포의 증식, 세포외 기질 장벽을 통한 주행성 내피세포의 이동, 모세혈관의 형성을 포함합니다. 생리적 및 병적 혈관 신생은 많은 동일한 세포 과정과 분자 신호 전달 네트워크를 이용하지만, 병적 혈관 신생에서 형성되는 구조는 종종 기능적으로 비정상적인 경우가 많습니다.
세계 혈관 신생 어세이 키트 시장은 최근 몇 년 동안 종양학 연구, 심혈관계 의약품 개발, 오가노이드 모델로의 적용을 중심으로 꾸준한 성장세를 유지하고 있습니다. 기술 유형별로는 in vitro 관 형성 실험이 주류를 이루는 가운데, in vivo 환경을 모방한 마이크로플루이딕스 3D 모델이 가장 빠르게 성장하고 있습니다. 가격 측면에서는 하이엔드 어세이는 기술적 장벽으로 인해 높은 수익률을 유지하고 있지만, 중국 업체들은 국내 대체품에 의한 가격 인하(30-50% 비용 절감)를 통해 중저가 시장으로 빠르게 침투하고 있습니다. 지역별로는 북미가 혈관 신생 어세이 키트의 세계 최대 시장으로 35% 이상의 점유율을 차지하고 있습니다. 이어 유럽과 아시아태평양이 그 뒤를 이었으며, 두 지역 모두 약 60%의 점유율을 차지했습니다. 높은 가격 민감도로 인해 아시아태평양 시장에서는 현지 브랜드의 점유율이 확대되고 있습니다. 향후 정밀의료 및 항혈관 신약개발에 대한 수요가 증가함에 따라 고감도 자동화된 분석이 경쟁의 초점이 될 것입니다. 또한 신흥 시장에서의 가격경쟁은 업계 재편을 더욱 가속화할 가능성이 있습니다.
이 보고서는 혈관 신생 어세이 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
혈관 신생 어세이 시장 규모, 추정치 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 혈관 신생 어세이에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Abcam
- Bio-Techne(Trevigen, R&D Systems)
- Thermo Fisher Scientific
- Cell Biolabs, Inc.
- BioVision, Inc
- PromoCell GmbH
- Merck KGaA
- Kollodis BioSciences
- Sartorius(Essen BioScience)
- Creative Bioarray
- ibidi GmbH
- Solarbio
유형별 부문
- In Vitro Assay Kit
- In Vivo Assay Kit
용도별 부문
- 학술기관
- 바이오테크놀러지 기업
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Angiogenesis Assay was estimated to be worth US$ 24.08 million in 2024 and is forecast to a readjusted size of US$ 39.93 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Angiogenesis is the tightly regulated process by which new blood vessels are formed from the existing vasculature. This process is physiologically important for development and wound healing, and is also a common driver in multiple diseases including rheumatoid arthritis, atherosclerosis, macular degeneration, and cancer. Angiogenesis occurs in response to a variety of molecular cues. Generally, the angiogenic process includes endothelial cell proliferation, chemotactic endothelial cell migration through the extracellular matrix barrier, and the formation of capillary tubes. Physiological and pathological angiogenesis utilize many of the same cellular processes and molecular signaling networks, however the structures that form during pathological angiogenesis are often functionally abnormal.
The global angiogenesis assay kit market has maintained steady growth in recent years, primarily driven by applications in oncology research, cardiovascular drug development, and organoid models. In terms of technology type, in vitro tube formation experiments dominate, while microfluidic 3D models, embracing the in vivo environment, are experiencing the fastest growth. Regarding pricing, high-end assays maintain high margins thanks to technological barriers, while Chinese manufacturers are rapidly penetrating the mid- and low-end markets through domestic substitution (reducing prices by 30%-50%). Regionally, North America is the largest global market for angiogenesis assay kits, holding over 35% of the market share, followed by Europe and Asia Pacific, which together hold nearly 60% of the market share. Due to cost sensitivity, the Asia Pacific market is seeing an increase in the share of local brands. In the future, as demand for precision medicine and anti-angiogenic drug development increases, highly sensitive, automated assays will become a key competitive focus. Furthermore, price competition in emerging markets is likely to further intensify industry consolidation.
This report aims to provide a comprehensive presentation of the global market for Angiogenesis Assay, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Angiogenesis Assay by region & country, by Type, and by Application.
The Angiogenesis Assay market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiogenesis Assay.
Market Segmentation
By Company
- Abcam
- Bio-Techne (Trevigen, R&D Systems)
- Thermo Fisher Scientific
- Cell Biolabs, Inc.
- BioVision, Inc
- PromoCell GmbH
- Merck KGaA
- Kollodis BioSciences
- Sartorius (Essen BioScience)
- Creative Bioarray
- ibidi GmbH
- Solarbio
Segment by Type
- In Vitro Assay Kit
- In Vivo Assay Kit
Segment by Application
- Academic Institution
- Biotech Companies
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Angiogenesis Assay company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Angiogenesis Assay in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Angiogenesis Assay in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Angiogenesis Assay Product Introduction
- 1.2 Global Angiogenesis Assay Market Size Forecast (2020-2031)
- 1.3 Angiogenesis Assay Market Trends & Drivers
- 1.3.1 Angiogenesis Assay Industry Trends
- 1.3.2 Angiogenesis Assay Market Drivers & Opportunity
- 1.3.3 Angiogenesis Assay Market Challenges
- 1.3.4 Angiogenesis Assay Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Angiogenesis Assay Players Revenue Ranking (2024)
- 2.2 Global Angiogenesis Assay Revenue by Company (2020-2025)
- 2.3 Key Companies Angiogenesis Assay Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Angiogenesis Assay Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Angiogenesis Assay
- 2.6 Angiogenesis Assay Market Competitive Analysis
- 2.6.1 Angiogenesis Assay Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Angiogenesis Assay Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiogenesis Assay as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 In Vitro Assay Kit
- 3.1.2 In Vivo Assay Kit
- 3.2 Global Angiogenesis Assay Sales Value by Type
- 3.2.1 Global Angiogenesis Assay Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Angiogenesis Assay Sales Value, by Type (2020-2031)
- 3.2.3 Global Angiogenesis Assay Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Academic Institution
- 4.1.2 Biotech Companies
- 4.2 Global Angiogenesis Assay Sales Value by Application
- 4.2.1 Global Angiogenesis Assay Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Angiogenesis Assay Sales Value, by Application (2020-2031)
- 4.2.3 Global Angiogenesis Assay Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Angiogenesis Assay Sales Value by Region
- 5.1.1 Global Angiogenesis Assay Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Angiogenesis Assay Sales Value by Region (2020-2025)
- 5.1.3 Global Angiogenesis Assay Sales Value by Region (2026-2031)
- 5.1.4 Global Angiogenesis Assay Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Angiogenesis Assay Sales Value, 2020-2031
- 5.2.2 North America Angiogenesis Assay Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Angiogenesis Assay Sales Value, 2020-2031
- 5.3.2 Europe Angiogenesis Assay Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Angiogenesis Assay Sales Value, 2020-2031
- 5.4.2 Asia Pacific Angiogenesis Assay Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Angiogenesis Assay Sales Value, 2020-2031
- 5.5.2 South America Angiogenesis Assay Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Angiogenesis Assay Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Angiogenesis Assay Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Angiogenesis Assay Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Angiogenesis Assay Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Angiogenesis Assay Sales Value, 2020-2031
- 6.3.2 United States Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Angiogenesis Assay Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Angiogenesis Assay Sales Value, 2020-2031
- 6.4.2 Europe Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Angiogenesis Assay Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Angiogenesis Assay Sales Value, 2020-2031
- 6.5.2 China Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Angiogenesis Assay Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Angiogenesis Assay Sales Value, 2020-2031
- 6.6.2 Japan Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Angiogenesis Assay Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Angiogenesis Assay Sales Value, 2020-2031
- 6.7.2 South Korea Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Angiogenesis Assay Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Angiogenesis Assay Sales Value, 2020-2031
- 6.8.2 Southeast Asia Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Angiogenesis Assay Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Angiogenesis Assay Sales Value, 2020-2031
- 6.9.2 India Angiogenesis Assay Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Angiogenesis Assay Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Abcam
- 7.1.1 Abcam Profile
- 7.1.2 Abcam Main Business
- 7.1.3 Abcam Angiogenesis Assay Products, Services and Solutions
- 7.1.4 Abcam Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.1.5 Abcam Recent Developments
- 7.2 Bio-Techne (Trevigen, R&D Systems)
- 7.2.1 Bio-Techne (Trevigen, R&D Systems) Profile
- 7.2.2 Bio-Techne (Trevigen, R&D Systems) Main Business
- 7.2.3 Bio-Techne (Trevigen, R&D Systems) Angiogenesis Assay Products, Services and Solutions
- 7.2.4 Bio-Techne (Trevigen, R&D Systems) Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.2.5 Bio-Techne (Trevigen, R&D Systems) Recent Developments
- 7.3 Thermo Fisher Scientific
- 7.3.1 Thermo Fisher Scientific Profile
- 7.3.2 Thermo Fisher Scientific Main Business
- 7.3.3 Thermo Fisher Scientific Angiogenesis Assay Products, Services and Solutions
- 7.3.4 Thermo Fisher Scientific Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.3.5 Thermo Fisher Scientific Recent Developments
- 7.4 Cell Biolabs, Inc.
- 7.4.1 Cell Biolabs, Inc. Profile
- 7.4.2 Cell Biolabs, Inc. Main Business
- 7.4.3 Cell Biolabs, Inc. Angiogenesis Assay Products, Services and Solutions
- 7.4.4 Cell Biolabs, Inc. Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.4.5 Cell Biolabs, Inc. Recent Developments
- 7.5 BioVision, Inc
- 7.5.1 BioVision, Inc Profile
- 7.5.2 BioVision, Inc Main Business
- 7.5.3 BioVision, Inc Angiogenesis Assay Products, Services and Solutions
- 7.5.4 BioVision, Inc Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.5.5 BioVision, Inc Recent Developments
- 7.6 PromoCell GmbH
- 7.6.1 PromoCell GmbH Profile
- 7.6.2 PromoCell GmbH Main Business
- 7.6.3 PromoCell GmbH Angiogenesis Assay Products, Services and Solutions
- 7.6.4 PromoCell GmbH Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.6.5 PromoCell GmbH Recent Developments
- 7.7 Merck KGaA
- 7.7.1 Merck KGaA Profile
- 7.7.2 Merck KGaA Main Business
- 7.7.3 Merck KGaA Angiogenesis Assay Products, Services and Solutions
- 7.7.4 Merck KGaA Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.7.5 Merck KGaA Recent Developments
- 7.8 Kollodis BioSciences
- 7.8.1 Kollodis BioSciences Profile
- 7.8.2 Kollodis BioSciences Main Business
- 7.8.3 Kollodis BioSciences Angiogenesis Assay Products, Services and Solutions
- 7.8.4 Kollodis BioSciences Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.8.5 Kollodis BioSciences Recent Developments
- 7.9 Sartorius (Essen BioScience)
- 7.9.1 Sartorius (Essen BioScience) Profile
- 7.9.2 Sartorius (Essen BioScience) Main Business
- 7.9.3 Sartorius (Essen BioScience) Angiogenesis Assay Products, Services and Solutions
- 7.9.4 Sartorius (Essen BioScience) Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.9.5 Sartorius (Essen BioScience) Recent Developments
- 7.10 Creative Bioarray
- 7.10.1 Creative Bioarray Profile
- 7.10.2 Creative Bioarray Main Business
- 7.10.3 Creative Bioarray Angiogenesis Assay Products, Services and Solutions
- 7.10.4 Creative Bioarray Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.10.5 Creative Bioarray Recent Developments
- 7.11 ibidi GmbH
- 7.11.1 ibidi GmbH Profile
- 7.11.2 ibidi GmbH Main Business
- 7.11.3 ibidi GmbH Angiogenesis Assay Products, Services and Solutions
- 7.11.4 ibidi GmbH Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.11.5 ibidi GmbH Recent Developments
- 7.12 Solarbio
- 7.12.1 Solarbio Profile
- 7.12.2 Solarbio Main Business
- 7.12.3 Solarbio Angiogenesis Assay Products, Services and Solutions
- 7.12.4 Solarbio Angiogenesis Assay Revenue (US$ Million) & (2020-2025)
- 7.12.5 Solarbio Recent Developments
8 Industry Chain Analysis
- 8.1 Angiogenesis Assay Industrial Chain
- 8.2 Angiogenesis Assay Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Angiogenesis Assay Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Angiogenesis Assay Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
